Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Orano Med LLC
Amgen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
National Cancer Institute (NCI)
Melanoma and Skin Cancer Trials Limited
ITM Solucin GmbH
Melanoma and Skin Cancer Trials Limited
University Health Network, Toronto
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
Olivia Newton-John Cancer Research Institute
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
University of Michigan Rogel Cancer Center
Jonsson Comprehensive Cancer Center
Imperial College London
TaiRx, Inc.
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
University Health Network, Toronto
University of Alberta
University of Iowa
Merck Sharp & Dohme LLC
ITM Solucin GmbH
Sinotau Pharmaceutical Group
University of California, San Francisco
University of Iowa
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Harbour BioMed (Guangzhou) Co. Ltd.
University Hospital, Basel, Switzerland
Uppsala University
23andMe, Inc.
Peking University
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
CHU de Quebec-Universite Laval
University Medical Center Goettingen
Wren Laboratories LLC
University of Iowa